title: A pilot study evaluating the effect of recombinant human bone morphogenetic protein-2 and recombinant human beta-nerve growth factor on the healing of Class III furcation defects in dogs.
abstract: BACKGROUND
  The quantity of regenerated bone induced by recombinant human bone morphogenetic protein-2 (rhBMP2) is encouraging, but sometimes the quality is inferior. Recombinant human beta-nerve growth factor (rh beta-NGF) plays a major role in bone remodeling. This study evaluates the quality and quantity of regenerated bone in periodontal regeneration following topical application of the two growth factors to Class III furcation defects.
  
  
  METHODS
  Thirty-six inflamed Class III furcation defects were created in six beagle dogs at sites of mandibular premolars 2, 3, and 4, and then biodegradable hydrogel incorporating rhBMP2 and rh beta-NGF was topically applied to the defects. The groupings were as follows: G1, untreated (control group A); G2, carrier alone (control group B); G3, 0.4% rhBMP2 + carrier; G4, 2% rh beta-NGF + carrier; G5, 0.4% rhBMP2 + 2% rh beta-NGF + carrier; and G6, 0.2% rhBMP2 + 1% rh beta-NGF + carrier. Eight weeks after application, the quality and quantity of regenerated tissue were evaluated by scanning electron microscopy observation, calcium/phosphorus ratio analysis, and histologic evaluation.
  
  
  RESULTS
  The regenerated bone in G5 exhibited the highest calcium/phosphorus ratio among all groups and showed a denser structure with more calcified substances on the collagen fiber surface than that in the other groups. Histomorphometric analysis revealed that 0.4% rhBMP2 + 2% rh beta-NGF promoted the highest percentage of periodontal regeneration among all groups.
  
  
  CONCLUSIONS
  The results of this pilot study suggest that a topical application of rhBMP2 and rh beta-NGF may improve the quality and quantity of regenerated bone in artificially created Class III furcation defects of beagle dogs.
authors.affiliation: Department of Periodontology, School of Stomatology, Shandong University, Jinan, China.
authors.forename: Xiang-Zhen
authors.initials: XZ
authors.lastname: Yan
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Ge
authors.forename: Qin-Feng
authors.initials: QF
authors.lastname: Sun
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Guo
authors.forename: Pi-Shan
authors.initials: PS
authors.lastname: Yang
mesh_terms: D000287:Administration, Topical; D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage*; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage; D001861:Bone Regeneration / Q000187:drug effects*; D002118:Calcium / Q000032:analysis; D004285:Dogs; D004337:Drug Carriers; D004338:Drug Combinations; D005260:Female; D017823:Furcation Defects / Q000188:drug therapy*; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D007249:Inflammation / Q000188:drug therapy; D020932:Nerve Growth Factor / Q000008:administration & dosage*; D010710:Phosphates / Q000032:analysis; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000008:administration & dosage; D013052:Spectrometry, X-Ray Emission; D016212:Transforming Growth Factor beta / Q000008:administration & dosage
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D004338:Drug Combinations; D010710:Phosphates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D020932:Nerve Growth Factor; D002118:Calcium